Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer

Author:

Ma Xiaocong1ORCID,Fang Weimin1,Wang Duo1,Shao Ni1,Chen Jifeng1,Nie Tianqi2,Huang Cuiqing3,Huang Yanyu4,Luo Liangping1,Xiao Zeyu1ORCID

Affiliation:

1. The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China

2. The 12th People’s Hospital of Guangzhou, Guangzhou 510620, China

3. Department of Ultrasound, Guangdong Women and Children Hospital, Guangzhou 511400, China

4. Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA

Abstract

Abnormal tumor vasculature and a hypoxic tumor microenvironment (TME) limit the effectiveness of conventional cancer treatment. Recent studies have shown that antivascular strategies that focus on antagonizing the hypoxic TME and promoting vessel normalization effectively synergize to increase the antitumor efficacy of conventional therapeutic regimens. By integrating multiple therapeutic agents, well-designed nanomaterials exhibit great advantages in achieving higher drug delivery efficiency and can be used as multimodal therapy with reduced systemic toxicity. In this review, strategies for the nanomaterial-based administration of antivascular therapy combined with other common tumor treatments, including immunotherapy, chemotherapy, phototherapy, radiotherapy, and interventional therapy, are summarized. In particular, the administration of intravascular therapy and other therapies with the use of versatile nanodrugs is also described. This review provides a reference for the development of multifunctional nanotheranostic platforms for effective antivascular therapy in combined anticancer treatments.

Funder

National Natural Science Foundation of China

Guangdong Basic and Applied Basic Research Foundation

Fundamental Research Funds for the Central Universities

Medical Joint Fund of Jinan University

Publisher

MDPI AG

Subject

Pharmaceutical Science

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3